Provider Briefing: Alprazolam XR Supply in 2026

If your patients are reporting difficulty filling Alprazolam XR prescriptions, they're not exaggerating. The extended-release formulation of Alprazolam has been subject to intermittent supply disruptions since 2020, and the situation remains challenging in 2026.

This briefing provides a clinical and practical overview of the current shortage landscape, its impact on prescribing, and the tools and strategies available to help your patients maintain continuity of care.

Shortage Timeline

The Alprazolam XR supply issues didn't appear overnight. Here's a condensed timeline:

• 2020: The COVID-19 pandemic triggered a significant increase in anxiety disorder diagnoses and benzodiazepine prescriptions. Supply chains — particularly for active pharmaceutical ingredients sourced internationally — experienced widespread disruptions.
• 2021–2022: The FDA Drug Shortage Database intermittently listed alprazolam products. DEA manufacturing quotas, designed to cap production of Schedule IV substances, became a bottleneck as demand outpaced supply.
• 2023–2024: While immediate-release Alprazolam supply largely stabilized, the extended-release formulation continued to experience sporadic shortages. Fewer generic manufacturers produce XR tablets compared to IR, making the supply more fragile.
• 2025–2026: Supply remains inconsistent. Availability varies significantly by region, dose strength (2 mg and 3 mg are the most affected), and manufacturer. Some pharmacies report reliable stock while others face chronic shortfalls.

Prescribing Implications

The ongoing shortage has several clinical considerations for prescribers:

Continuity of Care

Patients on stable Alprazolam XR regimens who are suddenly unable to fill their prescriptions face real medical risk. Abrupt benzodiazepine discontinuation can precipitate withdrawal seizures, rebound anxiety, insomnia, and autonomic instability. For patients who have been taking Alprazolam XR for more than a few weeks, unplanned gaps in treatment are medically significant.

Bridge Prescriptions

When a patient cannot locate Alprazolam XR, the most common bridge strategy is to convert to immediate-release Alprazolam, which is far more widely available. A typical conversion:

• Alprazolam XR 3 mg once daily → Alprazolam IR 1 mg three times daily
• Adjust based on individual patient response and tolerance

The total daily dose generally remains the same when converting between XR and IR formulations.

Alternative Benzodiazepines

If the clinical decision is to transition to a different benzodiazepine, consider:

• Clonazepam (Klonopin): Longer half-life (18–50 hours vs. 6–12 hours for Alprazolam), FDA-approved for panic disorder, generally well-stocked. Approximate equivalence: 0.5 mg Alprazolam ≈ 0.5 mg Clonazepam.
• Lorazepam (Ativan): Intermediate-acting, no active metabolites, preferred in hepatic impairment and elderly patients. Approximate equivalence: 0.5 mg Alprazolam ≈ 1 mg Lorazepam.

Cross-tapering is recommended rather than abrupt substitution, particularly for patients on higher doses or longer treatment durations.

Non-Benzodiazepine Considerations

For patients where the shortage provides an opportunity to reassess treatment, consider whether the ongoing use of a benzodiazepine is still the optimal approach. Evidence-based alternatives include:

• SSRIs/SNRIs (Sertraline, Paroxetine, Venlafaxine XR) as first-line pharmacotherapy for panic disorder
• Buspirone for generalized anxiety (not effective for panic disorder)
• Cognitive behavioral therapy (CBT) — the gold standard non-pharmacologic treatment for panic disorder

These options don't address acute needs but may be appropriate for long-term treatment planning.

Current Availability Picture

The availability landscape for Alprazolam XR in 2026 breaks down roughly as follows:

• 0.5 mg and 1 mg tablets: Generally available at most pharmacies, though intermittent shortages occur
• 2 mg tablets: Inconsistent availability; some regions and pharmacies report chronic difficulty stocking this strength
• 3 mg tablets: The most affected strength; many pharmacies are unable to maintain reliable stock

Generic manufacturers currently producing Alprazolam XR include Greenstone, Sandoz, Mylan, and Aurobindo, but not all are producing all strengths at all times.

Cost and Access

Cost remains a barrier for some patients, particularly those who are uninsured or underinsured:

• Generic Alprazolam XR cash price: $30–$90 for 30 tablets
• With discount cards: $15–$40 (GoodRx, SingleCare, RxSaver)
• Insurance: Typically covered as Tier 2/3; prior authorization and quantity limits are common

For patients facing cost barriers, discount programs and patient assistance resources can help. A patient-facing guide is available at how to save money on Alprazolam XR. For provider-specific cost navigation strategies, see how to help patients save money on Alprazolam XR.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a pharmacy inventory search tool that allows providers and their staff to check which pharmacies in a patient's area have Alprazolam XR in stock. This can be integrated into your workflow when writing prescriptions for medications with known supply issues.

Patient Communication

Consider proactively discussing the shortage with patients who are on Alprazolam XR or being started on it. Key points to cover:

• The shortage is a supply-side issue, not a prescribing or insurance issue
• They should plan refills 5–7 days in advance
• They should never stop the medication abruptly if they can't fill it — they should call your office first
• Direct them to Medfinder for pharmacy stock searches

Electronic Prescribing Tips

When e-prescribing Alprazolam XR:

• Consider including a note in the prescription that allows pharmacist substitution between manufacturers
• For patients in areas with severe shortages, consider writing for the IR equivalent as a backup, with a note explaining the clinical context
• Quantity limits and refill schedules should account for the reality that patients may need extra time to locate the medication

Looking Ahead

The structural factors driving the Alprazolam XR shortage — DEA quotas, limited generic manufacturers, and sustained demand — are unlikely to resolve quickly. Providers should plan for continued intermittent availability through at least the end of 2026.

Staying informed and having a proactive plan for affected patients will minimize treatment disruptions. The most effective approach combines clinical flexibility (willingness to use equivalent alternatives), practical tools (like Medfinder for Providers), and clear patient communication.

Final Thoughts

The Alprazolam XR shortage is a patient safety issue. Gaps in benzodiazepine therapy carry real medical risk, and providers are in the best position to ensure continuity of care through proactive planning, timely communication, and familiarity with equivalent alternatives.

For additional provider resources, visit medfinder.com/providers. For a step-by-step guide to helping patients locate this medication, see how to help your patients find Alprazolam XR in stock.